Business Description
Cyteir Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US23284P1030
Description
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.58 | |||||
| 9-Day RSI | 41.1 | |||||
| 14-Day RSI | 42.39 | |||||
| 6-1 Month Momentum % | -0.66 | |||||
| 12-1 Month Momentum % | 30.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CYTT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cyteir Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.94 | ||
| Beta | 0 | ||
| Volatility % | 14.31 | ||
| 14-Day RSI | 42.39 | ||
| 14-Day ATR ($) | 0.00162 | ||
| 20-Day SMA ($) | 3.01 | ||
| 12-1 Month Momentum % | 30.87 | ||
| 52-Week Range ($) | 1.67 - 3.19 | ||
| Shares Outstanding (Mil) | 36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cyteir Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cyteir Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cyteir Therapeutics Inc Frequently Asked Questions
What is Cyteir Therapeutics Inc(CYTT)'s stock price today?
The current price of CYTT is $3.01. The 52 week high of CYTT is $3.19 and 52 week low is $1.67.
When is next earnings date of Cyteir Therapeutics Inc(CYTT)?
The next earnings date of Cyteir Therapeutics Inc(CYTT) is 2025-02-06 Est..
Does Cyteir Therapeutics Inc(CYTT) pay dividends? If so, how much?
Cyteir Therapeutics Inc(CYTT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers